Precipio (PRPO) Projected to Announce Quarterly Earnings on Wednesday

Posted by Stanley Muller on Jul 27th, 2026

Precipio (NASDAQ:PRPO – Get Free Report) is anticipated to announce its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect Precipio to post earnings of ($2.00) per share and revenue of $1.6750 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Precipio (NASDAQ:PRPO – Get Free Report) last announced its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.81) earnings per share for the quarter. The firm had revenue of $6.71 million for the quarter. Precipio had a negative return on equity of 6.73% and a negative net margin of 3.57%.

Precipio Price Performance

Shares of NASDAQ PRPO opened at $23.68 on Monday. The firm has a market capitalization of $42.39 million, a PE ratio of -50.38 and a beta of 1.27. The company has a current ratio of 1.56, a quick ratio of 1.33 and a debt-to-equity ratio of 0.05. Precipio has a 1 year low of $13.80 and a 1 year high of $33.63. The firm’s 50-day moving average is $23.72 and its 200-day moving average is $25.18.

Institutional Investors Weigh In On Precipio

A number of hedge funds have recently modified their holdings of the business. Geode Capital Management LLC grew its position in shares of Precipio by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after purchasing an additional 789 shares during the period. Renaissance Technologies LLC raised its holdings in Precipio by 10.7% during the 4th quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after buying an additional 1,400 shares during the period. Finally, Susquehanna International Group LLP acquired a new stake in Precipio during the 3rd quarter worth approximately $194,000. Institutional investors and hedge funds own 10.45% of the company’s stock.

Analysts Set New Price Targets

PRPO has been the topic of several analyst reports. Wall Street Zen lowered shares of Precipio from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precipio in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Precipio currently has a consensus rating of “Sell”.

View Our Latest Analysis on PRPO

Precipio Company Profile

(Get Free Report)

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.